You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Diabetes Articles
Popular Diabetes Articles
Highly Recommended Diabetes Articles
Send a link to this page to your friends and colleagues.
Two years of statin therapy showed no effect on carotid intima-media thickness (IMT) in people with type 2 diabetes without apparent cardiovascular disease. However, there was a significantly lower cardiovascular event rate, according to researchers in the Netherlands.
A total of 250 patients with type 2 were given either a statin drug or placebo daily for two years. There was no significant change of carotid IMT over the two years in either group, but LDL cholesterol was lowered by 25 percent in the statin group and increased by 8 percent in the placebo group.
Cardiovascular events occurred in 12 patients in the placebo group and in two patients in the statin group.
Since there was no significant change in IMT, the researchers say that other methods should be used for identifying cardiovascular disease in type 2s.
—Diabetes Care, December 2004
Clinical adviser’s note: Initially, patients in the treatment group of this randomized study were given cerivastatin (U.S. brand name Baycol) 0.4 mg per day. When this drug was withdrawn from the market, the treatment was changed to Zocor (simvastatin) 20 mg per day without unblinding the study.
For more information on why the lipid-regulating drugs called statins are recommended for most people with diabetes, especially those over age 40 even if cholesterol levels are normal, see Dr. Einhorn’s article on page 18 of our November 2004 issue.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.